Filing summary
Issuer mismatch: The request identifies Crescent Biopharma, Inc., but the supplied filing is GlycoMimetics, Inc.’s Form 10-K. The filing covers the fiscal year ended December 31, 2015; it is not a standalone 2015 fourth-quarter filing.
Business context and reporting period
GlycoMimetics was a clinical-stage biotechnology company developing glycomimetic drug candidates. Its lead program, rivipansel, was licensed worldwide to Pfizer; other principal programs included GMI-1271 and preclinical candidate GMI-1359. The company had no approved drugs or product sales.
Financial performance and position
| Metric | 2015 | 2014 |
|---|---|---|
| Revenue | $20.1 million | $15.0 million |
| Research and development expense | $25.1 million | $19.6 million |
| General and administrative expense | $7.8 million | $6.6 million |
| Net loss | $12.8 million | $11.1 million |
| Net loss per share | $0.67 | $0.60 |
| Cash used in operating activities | $8.2 million | $4.3 million |
| Cash and cash equivalents at year-end | $46.8 million | $55.2 million |
- 2015 revenue was the $20.0 million Pfizer milestone triggered by dosing the first patient in rivipansel’s Phase 3 trial. Revenue in 2014 was a $15.0 million Pfizer milestone. Revenue was therefore milestone-dependent, not recurring product revenue.
- Operating loss was $12.8 million in 2015, versus $11.1 million in 2014. The filing provides no meaningful product gross margin, given the absence of product sales.
- At December 31, 2015, total assets were $48.5 million, total liabilities $8.0 million and stockholders’ equity $40.5 million. The filing reports no material borrowings or debt; liabilities were principally accrued expenses and deferred rent.
- Current assets were $47.2 million and current liabilities $7.7 million. The company reported an accumulated deficit of $87.2 million.
- For Q4 2015 specifically, revenue was approximately $35,000 and net loss was $8.9 million. The $10.4 million quarterly net income in Q2 reflected the Pfizer milestone and did not indicate recurring profitability.
Changes, outlook and risks
- Compared with 2014, revenue rose $5.0 million, while R&D expense rose $5.5 million and G&A expense rose $1.2 million. Higher R&D spending reflected the GMI-1271 AML trial, GMI-1359 preclinical and manufacturing work, and related staffing. Operating cash use increased despite the milestone receipt.
- Management estimated that year-end cash would fund operations into the first quarter of 2017, excluding potential future Pfizer milestones. The estimate depended on assumptions that could prove inaccurate; additional financing might be needed, and no new financing was committed.
- Pfizer’s Phase 3 RESET trial of rivipansel began in June 2015, with at least 350 planned participants. The filing reports Phase 2 improvements across several measures, but the primary endpoint and most reported time-to-event comparisons were not statistically significant; reduction in opioid use was statistically significant.
- Management expected the GMI-1271 AML Phase 1 portion to be completed and Phase 2 initiated in 2016, planned a multiple-myeloma trial in the second half of 2016, and anticipated an IND filing for GMI-1359 in the third quarter of 2016. These are forward-looking plans, not achieved outcomes.
- Key risks include clinical-trial failure or delay, dependence on Pfizer for rivipansel development and milestone or royalty income, need for additional capital, competition, regulatory approval and reimbursement uncertainty, and reliance on third parties for manufacturing and trials. Pfizer milestones and royalties are contingent; the company owed the University of Basel $2.0 million, equal to 10% of the 2015 milestone.
- The company reported no material legal proceedings. Its auditor issued an unqualified opinion on the financial statements; management concluded disclosure controls and internal control over financial reporting were effective. The auditor did not attest to internal control.
Important facts for investors to verify
- Confirm the issuer and filing: the supplied report is GlycoMimetics’ 2015 Form 10-K, not Crescent Biopharma’s filing.
- Check subsequent RESET trial enrollment, results and Pfizer’s continued development plans; the 2015 report does not establish clinical efficacy or approval.
- Assess cash burn and financing needs against the stated runway into Q1 2017, including whether later financing or milestone receipts occurred.
- Review the Pfizer agreement’s remaining milestone and royalty terms, termination provisions, and the University of Basel’s share of applicable payments.
- Distinguish milestone-driven revenue and quarterly income from recurring revenue and operating profitability.